INTRODUCTION
============

Traditionally, the role of radiotherapy (RT) for hepatocellular carcinoma (HCC) has been limited due to the relatively low liver tolerance to radiation, although many are not candidates for curative treatment or not adequately treated with transarterial chemoembolization (TACE), radiofrequency ablation (RFA), or sorafenib. Wellknown Barcelona Clinic Liver Cancer (BCLC) guidelines for HCC did not recommend RT as a primary treatment option for all stages of HCC. In clinical guidelines of the European Association for the Study of the Liver and European Organization for Research and Treatment of Cancer (EASL-EORTC), use of external beam radiotherapy (EBRT) was also limited due to the possibility of radiation-induced liver disease (RILD), and reasons for the benefits of three-dimensional conformal radiotherapy (3D-CRT) have only been shown in uncontrolled studies.

However, with increasing clinical use, RT has been considered reliable and effective for HCC treatment, depending on each stage. In addition, further development of modern RT technologies, including intensity-modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), and stereotactic body radiotherapy (SBRT), have expanded the indication of RT. In comparison to 3D-CRT, distinctions of IMRT include inverse treatment planning process and use of a large number of treatment fields or subfields, which provide high precision and exquisitely conformal dose distribution. Furthermore, the addition of multileaf collimator (MLC) enables non-uniform intensity profiles in various ways.

The role of RT is documented in several clinical guidelines. According to the most recent National Comprehensive Cancer Network (NCCN) guideline \[[@b1-cmh-2017-0073]\], EBRT is suggested as a locoregional treatment option for patients with unresectable HCC who are ineligible for transplantation, inoperable due to comorbidities, or those who have a local disease with/without minimal extrahepatic disease, with evidence level of 2B. Locoregional therapy, including EBRT, is also suggested as a treatment option for patients who have operable tumors, although resection is the preferred treatment. The guideline also mentions feasibility of modern RT and indications for SBRT. Korean Liver Cancer Study Group (KLCSG) has published the first comprehensive guidelines in 2003 with details regarding RT indication, and these guidelines have been updated recently in 2014 \[[@b2-cmh-2017-0073]\]. The KLCSG guideline provides multiple treatment suggestions for each stage based on the modified Union for International Cancer Control (mUICC) staging system, and lists the best options and alternatives. Based on recent perspectives, KLCSG is currently revising its 2014 guideline and discussing ways to further refine and expand the role of RT.

In this review, we describe the technical aspects of modern RT techniques for HCC along with their clinical applications in HCC, mainly according to the mUICC staging system. Furthermore, we introduce recent trends of RT, such as particle therapy.

MODERN RADIOTHERAPY TECHNIQUES
==============================

Intensity-modulated radiotherapy (IMRT)
---------------------------------------

Development of RT mainly focuses on improving two factors: accuracy and precision. Accuracy of RT implies that radiation can be delivered to the correct location each time, despite various uncertainties between the time of radiation treatment planning and the time of actual treatment. Precision of RT means the ability to control distribution of radiation to make sure that prescribed dose is administered exactly to tumor site, and that radiation is not delivered to surrounding normal tissues.

In the past, it was possible to perform treatment using two-dimensional fluoroscopic imaging plan and estimate radiation distribution in only one direction ("2D-RT"). Based on the development of computer engineering and radiology, computerized tomography (CT) images were used in planning simulation, while considering the three-dimensional positional relationship between tumor and surrounding normal tissues, in addition to more conformal treatments ("3D-CRT"). IMRT is the most advanced 3D-conformal treatment technique. It modulates the intensity of radiation delivered in each treatment direction, and selectively delivers the desired dose of radiation only to the tumor site while minimizing the amount of radiation entering normal tissue around tumor ([Fig. 1](#f1-cmh-2017-0073){ref-type="fig"}). The core of this treatment technique is the so-called "inverse treatment planning," in which the physician sets the ideal dose of targets and normal organs, and relative importance for tumor and surrounding organs in advance. Then, the machine computes and determines numbers and angles of beams. In the past, physicians performed target contouring and determined numbers and angles of beams, and then the machine performed RT ("Forward planning") ([Fig. 2](#f2-cmh-2017-0073){ref-type="fig"}).

Control of respiratory motion during radiation delivery
-------------------------------------------------------

Another critical issue in RT for HCC is the control of respiratory motion, as the liver moves in a considerable range during respiration. There are several ways to treat a moving tumor to ensure the tumor receives intended dose while reducing the dose to surrounding normal tissue. The strategies can be classified into motion-encompassing, breath-hold, forced shallow breathing with abdominal compression, respiratory gating, and real-time tumor tracking.

Motion-encompassing method refers to the covering of all possible positions of moving tumor through the entire breathing cycle using 4D-CT images. Subsequently, a large volume of normal tissue may be irradiated. Breath-hold method refers to letting the patient hold his or her breaths for a few seconds under deep inspiration, and then deliver radiation only when the liver is in a certain position. Forced shallow breathing is using a particular external device, such as an abdominal compressor, to allow the patient to breathe shallow during radiation therapy. Although breath-hold and forced shallow breathing might result in patient discomfort or inconvenience during treatment, it can reduce respiratory motion for liver tumors and enhance accuracy.

Currently, respiratory gating and real-time tumor tracking are considered the most advanced techniques. Respiratory gating method involves turning on the radiation beam only during a specific respiratory cycle, after accurately grasping the position of tumor according to the patient's respiratory cycle in advance, using 4D-CT images.

Real-time tracking method refers to tracking the movement of tumor along respiratory cycle using the surrogate on abdominal surface or internal fiducial marker, and then delivering radiation by following tumor inside the body. No respiratory control and abdominal compression are needed. This gating method using an external breathing signal is natural, noninvasive, and radiation-free; however, potential error might be that the signal does not accurately correlate with internal target position. On the other hand, the use of internal fiducial markers is an invasive method; however, it can improve the accuracy of treatment. Currently, one of the machines that are capable of tumor tracking is the CyberKnife system. Clinical feasibility of CyberKnife system has been demonstrated in several studies, especially SBRT papers. CyberKnife SBRT has been proven to be a safe and effective noninvasive treatment for HCC \[[@b3-cmh-2017-0073]-[@b7-cmh-2017-0073]\]. CyberKnife system consists of a pair of fluoroscopes in the ceiling coupled to a small X-band linear accelerator mounted on robotic arm, which can move according to the movement of inserted fiducial markers. Patients are encouraged to undergo implantation of three or more fiducial markers in the liver parenchyma around the perimeter of tumor before treatment, which would serve as radiographic landmarks for respiratory synchrony system and image guidance technique.

Image-guided radiotherapy (IGRT)
--------------------------------

IGRT is defined as RT that utilizes imaging to maximize accuracy throughout the entire treatment process, including precise targeting and normal tissue representation, radiation delivery, and adaptive plans for anatomic and biological changes over time for the patient. Of these, accurate target delineation, target relocalization to allow proper patient repositioning, and respiratory motion management have been the most challenging for patients with HCC, mainly due to the uncertain movement of the liver.

An essential feature of IGRT is that it allows image guidance therapy through in-room images obtained during radiation delivery ([Fig. 3](#f3-cmh-2017-0073){ref-type="fig"}). This leads to more precise treatment by reducing inter- and intra-fractional errors that result from daily changes in the liver to bones, breathing motion, and variation in shape and position of neighboring organs. Physicians can reduce target margins and spare additional normal tissue dose using 2D or 3D image guidance techniques (helical megavoltage CT, kilovoltage cone-beam CT (CBCT), and MV CBCT), compared to in-room laser beams and skin marks ([Fig. 3](#f3-cmh-2017-0073){ref-type="fig"}). Degree of error is evaluated by comparing reference images to in-room images. If the error is beyond allowable range and physicians see a need for adaptive planning, they should retake planning CT and restart treatment after new RT planning ([Fig. 4](#f4-cmh-2017-0073){ref-type="fig"}).

RADIOTHERAPY FOR EARLY STAGE (mUICC STAGE I/II) HCC
===================================================

Curative therapies can improve survival in early-stage HCC patients. Resection, percutaneous ethanol injection (PEI), and RFA have been considered valid local ablative treatments. However, when the effect is limited for reasons of primary tumor location (e.g., near the liver dome, or major vessels), RT may be considered as an alternative. Also, RT may be a feasible alternative for those who are inoperable or refuse surgery.

SBRT for early stage HCC
------------------------

Local high-dose RT, including SBRT, can be an appropriate alternative definitive or salvage treatment. In several prospective \[[@b8-cmh-2017-0073]-[@b17-cmh-2017-0073]\] ([Table 1](#t1-cmh-2017-0073){ref-type="table"}) or retrospective \[[@b3-cmh-2017-0073],[@b4-cmh-2017-0073],[@b18-cmh-2017-0073]-[@b29-cmh-2017-0073]\] ([Table 2](#t2-cmh-2017-0073){ref-type="table"}) papers, SBRT has been reported as a very effective, safe, and noninvasive treatment modality in primarily diagnosed or recurrent cases when size and position are acceptable. Honda Y, et al. demonstrated that SBRT combined with TACE is a safe and effective modality for locoregional treatment of small solitary primary HCC, with a 96% of high complete response (CR) rate \[[@b22-cmh-2017-0073]\]. Even for huge HCC ≥10 cm, SBRT could be a safe and effective treatment option. Jang WI, et al. suggested that there was a positive linear relationship between SBRT dose and 2-yr local control, overall survival (OS) rates, which were highest at \>54 Gy \[[@b24-cmh-2017-0073]\]. Sometimes, SBRT was also used for portal vein tumor thrombosis (PVTT) and/or inferior vena cava tumor thrombosis \[[@b23-cmh-2017-0073],[@b27-cmh-2017-0073]\], BCLC stage C HCC \[[@b27-cmh-2017-0073]\], or huge HCC ≥10 cm \[[@b28-cmh-2017-0073],[@b29-cmh-2017-0073]\], with acceptable response rates and survival outcomes. Wahl DR, et al. compared outcomes of patients with inoperable, nonmetastatic HCCs who underwent SBRT or RFA \[[@b30-cmh-2017-0073]\]. For tumors \<2 cm, there was no significant difference between RFA and SBRT in freedom from local progression (FFLP) (HR, 2.50; 95% CI, 0.72 to 8.67; *P*=0.15); however, for tumors ≥2 cm, RFA was associated with significantly worse FFLP (HR, 3.35; 95% CI, 1.17 to 9.62, *P* =0.025).

Radiotherapy as bridging treatment before liver transplantation
---------------------------------------------------------------

O'Connor JK, et al. reported that SBRT could be used as effective bridging treatment before liver transplantation \[[@b31-cmh-2017-0073]\]. In a recent study from Toronto General Hospital \[[@b32-cmh-2017-0073]\], 379 patients who underwent liver transplantation after SBRT (n=36), TACE (n=99), or RFA (n=244) were compared, to evaluate the safety and efficacy of bridging treatments. Drop-out rate and postoperative complication rates were similar between groups. The 3-year survival rate from time of transplant was 75% in SBRT group, 75% in TACE group, and 81% in RFA group, which were not significantly different. This showed that SBRT might be as effective and safe as TACE or RFA, when used to maintain candidacy of patients with HCC who are on the wait-list for a transplant for the first time.

RADIOTHERAPY FOR INTERMEDIATE STAGE (mUICC STAGE II/III) HCC
============================================================

In general, intermediate stage HCC is considered primarily for TACE. However, the effects of TACE may be limited if there is vascular shunting, recanalization around the tumor capsule, or development of multiple feeding vessels. TACE is contraindicated in patients with PVTT or inferior vena cava invasion, as it has potential risk of ischemic liver damage \[[@b33-cmh-2017-0073]\]. In addition, complete or massive necrosis is seldom observed following TACE, when the tumor is \>5 cm \[[@b34-cmh-2017-0073],[@b35-cmh-2017-0073]\]. In HCCs that either showed incomplete response after TACE or were unsuitable for TACE, RT can be useful as a complementary modality \[[@b36-cmh-2017-0073]-[@b39-cmh-2017-0073]\].

Radiotherapy for unresectable HCC after incomplete TACE
-------------------------------------------------------

In many prospective \[[@b40-cmh-2017-0073]-[@b45-cmh-2017-0073]\] or retrospective \[[@b36-cmh-2017-0073],[@b39-cmh-2017-0073],[@b46-cmh-2017-0073]-[@b49-cmh-2017-0073]\] papers, large unresectable HCCs were well treated with TACE followed by EBRT, and objective response rates (complete and partial responses) were achieved in about 63-76% of cases with 72-82% of 1-year survival rate, which is significantly higher compared to patients without EBRT ([Table 3](#t3-cmh-2017-0073){ref-type="table"}). A recent prospective phase II multicenter study \[[@b45-cmh-2017-0073]\] investigated the efficacy and toxicity of RT following incomplete TACE in unresectable HCCs. Here, patients with unresectable HCC who had viable tumor after TACE of no more than three courses were eligible, and median 54 Gy of 3D-CRT was delivered. Best objective infield response rate was achieved in 84% of patients, with 23% of CR rates and 61% of partial response (PR) rates within 12 weeks post-RT. The 2-year in-field progression-free survival (PFS), overall PFS, and OS rates were 45%, 29%, and 61%, respectively. These findings demonstrate that early application of 3D-CRT can be a promising option in multimodal approaches for patients with incomplete necrosis after TACE. Meng MB, et al. performed meta-analysis from five randomized controlled trials and 12 nonrandomized controlled clinical trials, which compared TACE+RT group and TACE alone group \[[@b50-cmh-2017-0073]\]. TACE+RT significantly improved survival rates and CR rates (OR, 2.58; 95% CI 1.64--4.06; *P*=0.0001). Rates of adverse events were not significantly different, except for elevation of total bilirubin level. Other meta-analyses \[[@b51-cmh-2017-0073],[@b52-cmh-2017-0073]\] also presented similarly favorable outcomes with TACE+RT compared to using TACE alone.

RADIOTHERAPY FOR ADVANCED STAGE (mUICC STAGE III/IV) HCC
========================================================

Radiotherapy for unresectable HCC with PVTT
-------------------------------------------

For patients who are unsuitable for TACE due to PVTT, value of RT has been especially noticeable in several prospective \[[@b44-cmh-2017-0073],[@b53-cmh-2017-0073]-[@b57-cmh-2017-0073]\] and retrospective studies \[[@b38-cmh-2017-0073],[@b58-cmh-2017-0073]-[@b67-cmh-2017-0073]\]. About 31% to 83% of objective response rates and median OS of 7 months to 34 months in responders have been reported \[[@b37-cmh-2017-0073],[@b59-cmh-2017-0073],[@b61-cmh-2017-0073],[@b67-cmh-2017-0073],[@b68-cmh-2017-0073]\] ([Table 4](#t4-cmh-2017-0073){ref-type="table"}). According to Korea's long-term follow-up data \[[@b59-cmh-2017-0073]\], authors reported clinical outcomes of patients who underwent RT for HCC with PVTT. With radiation volume including PVTT (±whole HCC), median survival time was 10.6 months, and 1-year survival rate was 43%. Furthermore, 3.6% of patients achieved CR and 24.3% of patients achieved PR, with 10% of grade 3-4 hepatic toxicity and 4% of gastroduodenal complications. TACE plus RT achieved significant survival advantage in HCC with PVTT than using TACE alone, according to propensity score matching \[[@b69-cmh-2017-0073]\]. Median survival time was 10.9 versus 4.1 months (*P*\<0.001) in all patients, 12.5 versus 4.4 months (*P* =0.002) in patients with PVTT involving the right/left portal vein, and 8.9 versus 4.0 months (*P*\<0.001) in patients with PVTT involving the main portal vein trunk. Based on another paper \[[@b62-cmh-2017-0073]\], TACE+RT showed longer OS in selected patients with locally advanced HCC in BCLC stage C who had macrovascular invasion in 96% of cases and received RT to vascular invasions, compared to sorafenib event after propensity score matching. Tang QH, et al. \[[@b61-cmh-2017-0073]\] also compared the outcomes of surgical resection plus 3D-CRT to tumor and PVTT with resection alone. There was a median survival advantage of 2.3 months (*P* =0.03), and 1-year survival rate was 52%. Stereotactic ablative radiotherapy (SABR) (median 40 Gy in 4-5 fractions) using CyberKnife was also suggested as a feasible treatment option \[[@b70-cmh-2017-0073]\]. In a multicenter retrospective study in Korea \[[@b67-cmh-2017-0073]\], outcomes of 985 patients who received RT for PVTT (±whole HCC) were analyzed, and response rate of PVTT was reported as 52%. Responders had significantly more prolonged survival (15 vs. 10 months) and equivalent RT dose \>45 Gy when given in combination with other treatments, and provided significantly better PVTT control and OS.

Recently, meta-analysis results of eight clinical studies regarding this subject were published in China \[[@b71-cmh-2017-0073]\]. TACE+RT significantly improved objective response rate (OR, 4.22; 95% CI, 3.07--5.80; *P*\<0.001) of PVTT and OS (HR, 0.69; 95% CI, 0.57--0.83; *P* =0.001), compared to TACE alone, although incidence of grade 3 or 4 leukopenia and thrombocytopenia was significantly higher.

Radiotherapy for huge HCC
-------------------------

RT can be very challenging to perform in some cases of very large unresectable HCCs. Although TACE has been frequently used in treatment of unresectable HCC, its limitation has also been well known, especially in large tumors, particularly regarding complicated blood supply and high incidence of residual viable tumor even after repeated treatment. Although surgical resection could also be tried in some cases, its indication is very limited. Shim SJ, et al. showed that TACE+RT offered more significant benefit than TACE alone when tumor size was larger \[[@b37-cmh-2017-0073]\]. According to the specific tumor size, 2-year survival rates in TACE+RT and TACE groups were 63% vs. 42% in 5--7 cm (*P*=0.22), 50% vs. 0% in 8--10 cm (*P*=0.03), and 17% vs. 0% in larger than 10 cm (*P*=0.002), respectively. In addition, Kim KH, et al. tried to find the most optimal treatment for huge HCCs ≥10 cm in patients who received various treatments at the same single institution \[[@b72-cmh-2017-0073]\]. Median OS was longer in TACE+RT group (15.3 months) and concurrent chemoradiotherapy (CCRT) group (12.8 months), compared to TACE alone group (7.5 months) and hepatic arterial infusion chemotherapy (HAIC) alone group (8.2 months); this indicated that huge unresectable HCCs treated with RT, either as CCRT or in combination with TACE, showed excellent intrahepatic control and prolonged survival.

RT for HCC with multiple intrahepatic metastases
------------------------------------------------

The role of local RT is more uncertain for HCC with multiple intrahepatic metastases. In one retrospective study \[[@b73-cmh-2017-0073]\], local RT to the main tumor was most beneficial with well-controlled intrahepatic tumors out of RT field. Patients with viable intrahepatic tumors out of RT field showed worse survival. Survival was similar when all lesions were covered by RT field, or lesions out of RT field were controlled by TACE. In a more recent study \[[@b57-cmh-2017-0073]\], TACE for intrahepatic metastases and localized CCRT were given to HCCs with portal vein invasion and intrahepatic metastasis. Objective response rate was 32.1%, and median PFS and OS were 4.5 months and 9.8 months, respectively. Incidence of grade 3--4 toxicity was low, manageable, and predictable, although two patients dropped out due to grade 3 nausea and vomiting.

Concurrent chemoradiotherapy for advanced stage HCC
---------------------------------------------------

Several studies have indicated that hepatic arterial infusion concurrent chemoradiation (HAICCRT) may be a feasible and effective alternative for unresectable liver-confined HCC with vascular invasion. The purpose of using HAIC in CCRT was to enhance local radio-therapeutic effect and to reduce intrahepatic HCC spread.

One pilot clinical study reported that CCRT improved response rates and survival for locally advanced HCC with portal vein invasion \[[@b54-cmh-2017-0073]\]. One month after localized CCRT, objective response was observed in 45% of patients, and 3-year survival rate was 24% which was significantly better compared to non-responders. More recently, the same institution showed treatment outcomes of 30 HCCs with portal vein invasion and intrahepatic metastasis \[[@b57-cmh-2017-0073]\]. After TACE for intrahepatic metastasis, localized CCRT (45 Gy in 25 fractions) was used to treat the main HCC with PVT. Objective response rate was about 30% and median OS was 9.8 months, without any severe adverse events. Review of nationwide multi-center HCC cohort (stage III-IV, CP-A) showed that patients who underwent definitive CCRT as initial treatment showed significantly better OS (median 11.4 versus 6.6 months, *P* =0.02) than matched patients who did not receive CCRT \[[@b74-cmh-2017-0073]\]. CCRT followed by HAIC in locally advanced HCC could even increase resectability by down-staging tumors and increasing functional residual liver volume, and 5-year OS was significantly increased to 50% (versus 10%) \[[@b75-cmh-2017-0073],[@b76-cmh-2017-0073]\]. In addition, EBRT can significantly relieve symptoms that are caused by locally advanced HCC or metastatic tumors, and even a prolongation of survival period can be expected \[[@b77-cmh-2017-0073],[@b78-cmh-2017-0073]\].

DOSE CONSTRAINTS
================

Development of improved treatment planning and dose delivery methods, such as 3D-CRT and IMRT, provided a mechanism not only to target hepatic lesions while sparing uninvolved hepatic parenchyma but also to precisely measure radiation dose delivered to both tumor volume and surrounding normal tissue. Despite technical advances, RILD still remains to be a side effect that presents significant concerns when planning RT for HCC.

RILD is a clinical syndrome of anicteric hepatomegaly, ascites, and elevated liver enzymes (particularly serum alkaline phosphatase) that occurs typically 2 weeks to 4 months after completion of hepatic irradiation. Tolerance of the whole liver to radiation is low, and RILD is seen in 5--10% of patients treated with 30--35 Gy to the whole liver, based on several Radiation Therapy Oncology Group (RTOG) studies in the 1970's and 1980's. For this reason, radiation has traditionally played a limited role in the treatment of liver tumors. However, treatment of liver parts using higher radiation doses is possible without adverse effects, as long as an adequate volume of normal liver is saved.

While the Emami report established baseline liver tolerance doses based on literature reports of toxicity \[[@b79-cmh-2017-0073]\], later studies provided more detailed assessment and guidelines regarding the risk of hepatotoxicity for given RT doses. At the University of Michigan \[[@b80-cmh-2017-0073]\], dose-volume tolerance for RILD using the Lyman-Kutcher-Burman (LKB) normal tissue complication probability (NTCP) model was described. They demonstrated that the liver exhibits a large volume effect for RILD, suggesting that the mean liver dose may be useful in ranking radiation plans. No cases of RILD were observed when the mean liver dose was \<31 Gy. Furthermore, multivariate analysis demonstrated that, in addition to NTCP and the mean liver dose, a primary hepatobiliary cancer diagnosis (vs. liver metastases), bromodeoxyuridine hepatic artery chemotherapy (vs. fluorodeoxyuridine chemotherapy), and male gender were associated with RILD. In a preclinical study \[[@b81-cmh-2017-0073]\] that treated rat cirrhosis model with mildly impaired liver function, combined treatment of partial RT plus 5-FU resulted in a significantly high incidence of lethal liver injury. According to Dawson LA's review paper \[[@b82-cmh-2017-0073]\], if the effective liver volume irradiated is less than 25%, very high RT doses (\>100 Gy) may be delivered with little risk of liver toxicity, as long as the liver function is proper. In addition, RT tolerance of the liver is reduced in patients with primary liver cancer versus metastases. The mean liver doses associated with 5% risk of classic RILD for primary and metastatic liver cancer are 28 Gy and 32 Gy, respectively, in 2 Gy per fraction.

According to recent papers \[[@b83-cmh-2017-0073],[@b84-cmh-2017-0073]\], there are several dose-volumetric parameters related to the risk of RILD, which are also included in the 2014 KLCSG guidelines. Tumor volume must be limited to ≤70% of the total liver volume, and liver volume receiving ≥30 Gy must be constrained to ≤60% of total liver volume on dose-volume histograms for 3D-RT planning. For SBRT, normal liver volume receiving a total dose of \<15 Gy must be ≥700 mL, or the mean normal liver dose (liver minus gross tumor volume) must be limited to \<28 Gy in 2-Gy fractions. Although additional studies for liver tolerance to radiation are still needed, several institutions have similarly applied dose--volume histogram parameter-based RT guidelines.

CHARGED PARTICLE THERAPY
========================

Charged particle therapy (CPT), such as proton and carbon ion therapy, is a form of radiotherapy with superior depth dose distribution compared to photon radiotherapy. This superiority in depth dose distribution is attained by the energy-dependent specific range of charged particles within the tissues and the Bragg peak, which is the sharp peak of energy deposit just before stopping the particle. Consequently, tumors can be treated more efficiently with less toxicity by charged particles than by photons on theoretical grounds, even in the cirrhotic liver with limited hepatic functional reserve. Some retrospective and prospective studies have reported encouraging outcomes with proton or carbon beam therapy in patients with HCC. Local control rates were 88%-98% at 2-5 years, with very low incidence of severe toxicity.

Proton beam therapy
-------------------

At the University of Tsukuba, long-term results of proton beam therapy (PBT) for HCCs were reported \[[@b85-cmh-2017-0073]-[@b88-cmh-2017-0073]\]. A total dose of 77.0 gray-equivalent (GyE) in 35 fractions was administered for tumors located within 2 cm of a digestive organ, 72.6 GyE in 22 fractions was administered for tumors located within 2 cm of the porta hepatis, and 66.0 GyE in 10 fractions was administered for peripheral tumors located more than 2 cm from both GI tract and porta hepatis. The 5-year survival was 23.5%, and local control rate was 86.9%. For a patient subgroup having BCLC stage 0/A HCCs, 5-year local control, PFS, and OS rates were much higher (94%, 28%, and 69%). Otherwise, there were very few acute reactions to treatment, in addition to a few grade 2 or more severe sequelae. So far, the largest prospective study of PBT for HCC was reported by the Loma Linda University Medical Center \[[@b89-cmh-2017-0073],[@b90-cmh-2017-0073]\]. After 63 GyE in 15 fractions of PBT, 20% had experienced local treatment failure, and median PFS was 36 months. No acute toxicity that required treatment interruption was found; however, five cases of grade 2 gastrointestinal bleeding or ulceration near the irradiated area were observed in patients who were treated in earlier period. In another phase II study of MGH \[[@b91-cmh-2017-0073],[@b92-cmh-2017-0073]\], 67.5 GyE and 58.05 GyE in 15 fractions for peripheral and central tumors were delivered, and 94% of favorable 2-year local control rate was reported. No local recurrence was reported with ≥60 GyE, and median PFS and OS were 13.9 months and 49.9 months, respectively. In other prospective studies \[[@b93-cmh-2017-0073]-[@b95-cmh-2017-0073]\], PBT showed about 95% of 2-year local control rates and 63-66% of 2-yr OS rates ([Table 5](#t5-cmh-2017-0073){ref-type="table"}). In a recent interim analysis of prospective randomized clinical trial comparing PBT and TACE \[[@b96-cmh-2017-0073]\], 2-year local control and PFS rates were higher with PBT (88% vs. 45%, 48% vs. 31%), although they were not significantly different. The total number of hospitalization days was significantly shorter in patients with PBT (24 vs. 166 days, *P*\<0.001). Pathologic complete response was achieved in 10% of TACE group and 25% of PBT group, who underwent liver transplantation after treatment. There was a trend toward improved 2-year local control (88% vs. 45%, *P*=0.06) and PFS (48% vs. 31%, *P*=0.06) favoring PBT.

Excellent local tumor control was reported, even in tumors with portal vein invasion ([Table 5](#t5-cmh-2017-0073){ref-type="table"}) \[[@b97-cmh-2017-0073]-[@b99-cmh-2017-0073]\]. Sugahara S, et al. \[[@b98-cmh-2017-0073]\] demonstrated that 2-year PFS and OS rates were 91% and 33-57% after PBT for HCC with PVTT, without treatment-related severe complications. Kim, et al. \[[@b93-cmh-2017-0073]\] also treated HCC with PVT, and local recurrence was noted in only 12% of patients during follow-up period, without local recurrence or severe gastrointestinal toxicity. In addition, proper local control rates can be expected for HCC patients with large tumors (87% at 2 years for tumors \>10 cm) or portal tumors (86% at 3 years), as well as for elderly patients (100% at 3 years for patients aged ≥80 years) \[[@b100-cmh-2017-0073]-[@b103-cmh-2017-0073]\]. Even for recurrent tumors after PBT, repeated PBT can be safely delivered with an excellent local control rate of 87.8% at 5 years \[[@b104-cmh-2017-0073]\].

With concerns about gastrointestinal toxicities and hepatic insufficiencies, Kawashima M, et al. \[[@b105-cmh-2017-0073]\] analyzed dose-volume histogram of 60 patients with HCC who were treated by PBT, and reported ICG R15 and V30 as useful predictors. According to the location of tumor, a risk-adapted simultaneous integrated boost technique could be utilized to avoid gastrointestinal toxicities. When PTV overlaps the planning organ at risk volume (PRV) of gastrointestinal tract, 50--60 GyE in 10 fractions was prescribed to PTV minus the overlapping volumes, whereas the dose to overlapping volumes was restricted to 30 GyE in 10 fractions \[[@b106-cmh-2017-0073]\]. Mizumoto M, et al. \[[@b86-cmh-2017-0073]\] also suggested risk-adapted selection scheme dose fractionation schedules. They adopted a small fraction dose schedule of 77 GyE in 35 fractions with gastrointestinal tract avoidance as far as possible, after 40--50 GyE for tumors proximal to the alimentary tract with reduced risk of gastrointestinal toxicities.

Carbon ion beam therapy
-----------------------

Although it is expected that the biological benefits of high relative biological effectiveness (RBE) and high linear energy transfer (LET) of carbon ion beam would offer better treatment efficacy than photon or PBT, clinical experience for carbon ion beam is not yet extensive.

The first clinical result of carbon ion therapy for HCC was published by the NIRS in 2004 \[[@b107-cmh-2017-0073]\]. In 24 patients who were enrolled in this study and received 49.5 GyE-79.5 GyE in 15 fractions, 3-year local control and OS rates were 81% and 50%, respectively. The OS rates of patients who had not received previous treatment for HCC were significantly higher than those who did. In particular, there was no local recurrence in patients receiving more than 72 GyE, and severe adverse events were not reported at any dose level. To date, NIRS researchers have conducted several other clinical trials for HCC with short-course irradiation regimens. A four-fraction regimen, with a total dose of 52.8 GyE, also yielded a high local control rate of 94% at 3 years \[[@b108-cmh-2017-0073]\]. Although local control rates for porta hepatis lesions were slightly worse than those for non-porta hepatis lesions, the difference was not statistically significant (88 vs. 96%, *P* =0.306) \[[@b109-cmh-2017-0073]\]. Two-fraction regimens are now being adopted with minor adverse events only \[[@b110-cmh-2017-0073]\], and follow-up clinical data is not yet available. Other hypofractionated regimens with dose escalation have been also studied, and mature data will be reported in the near future.

Komatsu S, et al. compared the clinical outcomes of PBT (278 tumors) to carbon ion therapy (108 tumors) in patients who were treated at the same institution \[[@b111-cmh-2017-0073]\]. The 5-year local control rates for PBT and carbon ion were 90% and 93%, respectively. For tumors \<5cm, local control rates were similar between two modalities (96% vs. 95%); however, the rates were slightly lower with PBT than carbon ion therapy for larger tumors (84% vs. 91% for tumors of 5-10cm; 43% vs. 80% for tumors \>10cm). In meta-analysis of 70 non-comparative observational studies (73 cohorts; 53 with photon therapy, and 20 with CPT) \[[@b112-cmh-2017-0073]\], the median radiation dose was higher in CPT cohorts compared to SBRT and conventional RT cohorts, while the median rate of patients with child-pugh A class was higher in CRT cohorts than in other cohorts. Additionally, median tumor size, rate of male, rate of patients with ECOG PS 0--1, or median HCC patients with tumor vascular thrombosis did not significantly differ between groups. The OS, PFS, and local control rates were significantly higher for CPT than those for conventional RT, while they were similar to SBRT in patients with HCC. Furthermore, high-grade acute and late toxicities were lower for CPT compared to conventional RT or SBRT.

So far, CPT generally showed better local control and survival rates than photon-based RT series, although a direct comparison is difficult due to differences in patient characteristics. Although facilities for CPT have been limited to this day, the use of CPT is anticipated to increase in the near future.
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![Comparison of treatment volumes by various radiotherapy RT technology involving 2D radiotherapy, 3D conformal radiotherapy (3D-CRT), and intensity modulated radiotherapy (IMRT). IMRT is the most advanced 3D-conformal treatment technology. It modulates the intensity of radiation delivered in each treatment direction, and selectively delivers the desired dose of radiation only to the tumor site, while minimizing the amount of radiation entering sensitive normal organs around the tumor with high precision.](cmh-2017-0073f1){#f1-cmh-2017-0073}

![Concept of inverse planning of intensity modulated radiotherapy (IMRT). In the past, physicians performed target contouring and determined numbers and angles of the beams, and then the machine performed radiotherapy ("forward planning"). The core of IMRT technique is the socalled "inverse planning," in which the physician sets ideal dose of targets and normal organs, and relative importance for the tumor and surrounding organs in advance. Then, the machine computes and determines numbers and angles of the beams.](cmh-2017-0073f2){#f2-cmh-2017-0073}

![Illustration of image-guided radiotherapy (IGRT) with daily setup using three-dimensional volumetric imaging modality. Matching between "reference images" using three-dimensional reconstruction of planning computed tomography images and in-room cone-beam computed tomography images are performed on each day of treatment.](cmh-2017-0073f3){#f3-cmh-2017-0073}

![Workflow of image-guided radiotherapy (IGRT). An essential feature of IGRT is that it allows image guidance therapy through in-room images obtained during radiation delivery. Physicians can reduce target margins and spare additional normal tissue dose using 2D or 3D image guidance techniques (helical megavoltage CT (MVCT), kilovoltage cone-beam CT (CBCT), and MV CBCT), compared to in-room laser beams and skin marks. Degree of error is evaluated by comparing reference images with in-room images at every treatment time. If the error is beyond the allowable range and physicians sees a need for adaptive planning, they should retake a planning CT and restart treatment after new RT planning.](cmh-2017-0073f4){#f4-cmh-2017-0073}

###### 

Prospective studies on SBRT for hepatocellular carcinoma

  Reference                                             Institutions                                              Design                                                                  RT Aim               Patient number                               Indication                                                                 Median size (range), cm    Dose                                                                          Median f/u (range), mo   Local control                    Overall survival
  ----------------------------------------------------- --------------------------------------------------------- ----------------------------------------------------------------------- -------------------- -------------------------------------------- -------------------------------------------------------------------------- -------------------------- ----------------------------------------------------------------------------- ------------------------ -------------------------------- ----------------------------------
  Herfarth KK, et al. \[[@b8-cmh-2017-0073]\] (2001)    Germany, Heidelberg Univ.                                 Phase I/II                                                              Definitive/Salvage   HCC/CCC (4/54)                               Unresectable liver tumor \<3 tumors, \<6 cm                                                           Dose escalation 14-26 Gy/1 fx                                                 6 (1-26)                 81% (18 mo)                      
  Tse RV, et al. \[[@b9-cmh-2017-0073]\] (2008)         Canada, Princess Margaret Hospital                        Phase I                                                                 Definitive/Salvage   HCC/CCC (31/10)                              CP-A, unresectable, previous Tx allowed                                                               Median 36 (24-54) Gy/6 fx                                                     18 (11-39)               65% (1 yr)                       48% (1 yr)
  Wulf J, et al. \[[@b10-cmh-2017-0073]\] (2006)        Switzerland                                               Prospective                                                             Definitive           HCC+CCC/mets (5/51)                          Unavailable for other Tx                                                                              Low dose : 30 Gy/3 fx or 28 Gy/4 fx High dose : 36-38 Gy/3 fx or 26 Gy/1 fx   HCC+CCC : 15 (2-48)      HCC+CCC : 83%                    HCC+CCC : 76% (1 yr), 61% (2 yr)
  Goodman KA, et al. \[[@b11-cmh-2017-0073]\] (2010)    MSKCC                                                     Phase I dose escalation                                                 Definitive/Salvage   HCC/mets (2/24)                              CP-A, unresectable, tumors \< 5                                                                       Dose escalation 18-30 Gy/1 fx                                                 17 (2-55)                77% (1 yr)                       50% (2 yr)
  Cárdenes HR, et al. \[[@b12-cmh-2017-0073]\] (2010)   United States, Indiana Univ.                              Phase I dose escalation                                                 Definitive           All HCC (17)                                 CP-A, CP-B, 1-3 lesions, ≤ 6cm, PVT allowed,                                                          CP-A : 36-48 Gy/3 fx CP-B : 40 Gy/5 fx                                        24 (10-42)               100%                             75% (1 yr) 60% (2 yr)
  Andolino DL, et al. \[[@b13-cmh-2017-0073]\] (2011)   United States, Indiana Univ.                              Phase II                                                                Definitive           All HCC (60)                                 CP-A, CP-B, liver-confined HCC, prior TACE included                        3.2 (1-6.5)                CP-A : 44 Gy/3 fx CP-B : 40 Gy/5 fx                                           27 (2-52)                90% (2 yr)                       67% (2 yr)
  Price TR, et al. \[[@b14-cmh-2017-0073]\] (2012)      United States, Indiana Univ.                              Phase I/II                                                              Definitive/Salvage   All HCC (26)                                 CP-A, CP-B, ≤3 tumors, single≤6cm, multiple≤sum 6cm, previous Tx allowed   GTV volume: 34 (2-95) cc   CP-A: 48 Gy/3 fx CP-B: 40 Gy/5 fx                                             13 (3-42)                CR + PR: 73%                     77% (1 yr) 60% (2 yr)
  Kang JK, et al. \[[@b15-cmh-2017-0073]\] (2012)       Korea, Korea Inst. Of Radiological and Medical Sciences   Phase II                                                                Salvage              All HCC (47)                                 CP-A, CP-B, inoperable, incomplete response after TACE, PVT allowed        2.9 (1.3-7.8)              57 (42-60) Gy/3 fx                                                            17 (6-38)                95% (2 yr)                       69% (2 yr)
  Bujold A, et al. \[[@b16-cmh-2017-0073]\] (2013)      Canada, Toronto Univ.                                     Phase I/II \[Trial 1\], immediately subsequently phase II \[Trial 2\]   Definitive           All HCC (102) (trial 1 : 50, trial 2 : 52)   CP-A, PVT allowed, \[trial 2\] ≤ 5 tumors, \<15cm                          7.2 (1.4-23.1)             36 (24-54) Gy/6 fx                                                            31 (2-36)                87% (1 yr)                       Median 17 mo
  Kim JW, et al. \[[@b17-cmh-2017-0073]\] (2016)        Korea, Yonsei Cancer Center                               Phase I                                                                 Definitive/Salvage   All HCC (18)                                 CP-A, CP-B, ≤3 tumors, single≤5cm, multiple≤sum 6cm, previous Tx allowed   1.9 (1.0-3.3)              Dose escalation 36-60 Gy/4 fx                                                 23 (11-38)               Radiologic CR: 89%, 49% (2 yr)   69% (2 yr)

HCC, hepatocellular carcinoma; CCC, cholangiocellular carcinoma; CP, child-pugh; PVT, portal vein thrombosis; TACE, transcatheter arterial chemoembolization; GTV, gross tumor volume; CR, complete response; PR, partial response.

###### 

Retrospective studies on SBRT for hepatocellular carcinoma

  Reference                                            Institutions                                                     Design                                                     RTAim                   Patient number                          Indication                                                                                                                                 Median size (cm)   Dose                                  Median f/u (range), mo   Local control                                        Overall survival
  ---------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------- ----------------------- --------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ------------------ ------------------------------------- ------------------------ ---------------------------------------------------- -------------------------------------------------------------------------------------------------------------
  Choi BO, et al. \[[@b18-cmh-2017-0073]\] (2006)      Korea, Catholic University of Korea                              Linac                                                      Definitive/Salvage      20                                      CP-A, CP-B, single lesion, previous TACE, PEI, RFA included                                                                                3.8 (2-6.5)        50 Gy/5 or 10 fx                      23 (3-55)                100%                                                 70% (1 yr), 43% (2 yr)
  Choi BO, et al. \[[@b19-cmh-2017-0073]\] (2008)      Korea, Catholic University of Korea                              Cyberknife                                                 Definitive/Salvage      31 (22 : SBRT alone, 9 : TACE + SBRT)   CP-A, CP-B, ≤5cm, PVT surrounding near HCC, previous TACE, PEI, RFA included advanced HCC + PVT -\> TACE + SBRT Small HCC -\> SBRT alone                      33 (30-39) Gy/3 fx                    11 (2-19)                100%                                                 81% (1 yr)
  Kwon JH, et al. \[[@b20-cmh-2017-0073]\] (2010)      Korea, Catholic University of Korea                              Cyberknife                                                 Definitive/Salvage      42                                      CP-A, CP-B, ≤100 cc, unavailable for other local therapies, inoperable, residual lesion after previous Tx, only targets liver parenchyme                      30-39 Gy/ 3 fx                        29 (8-49)                72% (1 yr), 68% (3 yr)                               93% (1 yr), 59% (3 yr)
  Seo YS, et al. \[[@b21-cmh-2017-0073]\] (2010)       Korea, Korea Inst. of Radiological and Medical Sciences          Cyberknife                                                 Salvage                 38                                      CP-A, CP-B,\< 10 cm, all with TACE failure                                                                                                                    33-57 Gy/ 3-4 fx                      15 (3-27)                66% (2 yr)                                           61% (2 yr)
  Louis C, et al. \[[@b3-cmh-2017-0073]\] (2010)       Belgium, University Hospital Domaine Universitaire Sart Tilman   Cyberknife                                                 Definitive/Salvage      25                                      CP-A, CP-B, PVT allowed, previous TACE, op, RFA, nexavar included                                                                          4.5 (1.8-10)       45 Gy/3 fx                            13 (1-24)                95% (1 yr)                                           79% (1 yr)
  Huang WY, et al. \[[@b4-cmh-2017-0073]\] (2012)      Taiwan, Tri-Service General Hospital                             Cyber knife, matched pair analysis (SBRT vs. other/noTx)   Salvage                 36                                      CP-A, CP-B, CP-C, All undergone prior Tx, but tumor progressed, unresectable                                                               4.4 (1.1-12.3)     37 (25-48 Gy)/ 4-5 fx                 14 (2-35)                88% (1 yr), 75% (2 yr)                               64% (2 yr)
  Honda Y, et al. \[[@b22-cmh-2017-0073]\] (2013)      Japan, Hiroshima Univ.                                           Linac, TACE alone vs. TACE -\> SBRT                        Salvage                 30                                      CP-A, CP-B, solitary, ≤3cm, all prior TACE, no PVT, no EHM                                                                                 1.6 (1-3)          48 Gy/4 fx or 60 Gy/8 fx              12 (6-38)                100%                                                 100% (1 yr), 100% (3 yr)
  Xi M, et al. \[[@b23-cmh-2017-0073]\] (2013)         China, Sun Yat-sen Univ.                                         VMAT                                                       Definitive/Salvage      41                                      CP-A, all with PVT/IVCT, targets thrombosis, unresectable                                                                                                     36 (30-48) Gy/6 fx                    10 (4-25)                95%                                                  50% (1 yr)
  Jang Wl, et al. \[[@b24-cmh-2017-0073]\] (2013)      Korea, Korea Inst. of Radiological and Medical Sciences          Cyberknife                                                 Definitive/Salvage      108                                     CP-A, CP-B, unsuitable for other Tx or incomplete TACE                                                                                     3 (1-7)            51 (33-60)/3 fx                       30 (4-81)                87% (2 yr)                                           63% (2 yr)
  Sanuki N, et al. \[[@b25-cmh-2017-0073]\] (2014)     Japan, Ofuna Chuo Hospital                                       Linac                                                      Definitive/Salvage      185                                     CP-A, CP-B, single, unresectable, no LN mets or EHM                                                                                        2.7 (1-5)          CP-A : 40 Gy/5 fx CP-B : 35 Gy/5 fx   24 (3-80)                91% (3 yr)                                           70% (3 yr)
  Culleton S, et al. \[[@b26-cmh-2017-0073]\] (2014)   Canada, Princess Margaret Cancer Centre                          3D-CRT, IMRT, or VMAT                                      Definitive/Salvage      29                                      CP-B, \<10cm, \<5 tumors, life expectancy \>3 months, KPS \> 60%, unresectable, unsuitable for liver transplantation                       8.66 (4.1-26.6)    median 30 Gy/6 fx                                              12 SD, 2 PR 6 intrahepatic PD (outfield)             Median 7.9 months, 32% (1 yr)
  BCLC-C                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Bae SH, et al. \[[@b27-cmh-2017-0073]\] (2013)       Korea, Korea Inst. of Radiological and Medical Sciences          Cyberknife                                                 Definitive/Palliative   35                                      BCLC-C, CP-A, CP-B, vascular invasion or extrahepatic metastasis                                                                                              45 (30-60) Gy/3-5 fx                  14 (1-44)                69% (1 yr), 51% (3 yr)                               52% (1 yr), 21% (2 yr)
  Huge HCC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Que JY, et al. \[[@b28-cmh-2017-0073]\] (2014)       Taiwan, Chi Mei Medical Center                                   Cyberknife                                                 Definitive/Salvage      22                                      CP-A, CP-B, ≥10 cm, ECOG≤2                                                                                                                 11.36 (10-18)      mainly 40 Gy/5 fx (26-40)             11.5 (2-46)              56 % (1 yr), Response rate 86.3%                     Median 11 mo, 50% (1 yr)
  Zhong NB, et al. \[[@b29-cmh-2017-0073]\] (2014)     China, Fuzhou General Hospital                                   Total body gammaray stereotactic radiotherapy system       Salvage                 72                                      Incomplete TACE -\> SBRT, ≥10cm, ECOG≤2                                                                                                    12.6 (10.8-16.5)   35.7 (33.8-39)/ 6 fx                  18 (4-70)                Response rate 79.1%, low incidence of recur (8.3%)   Median 10.8 mo, 38% (1 yr), 12% (3 yr), 3% (5 yr), significantly higher with tumor encapsulation (56%, 1yr)

CP, child-pugh; TACE, transcatheter arterial chemoembolization; PEI, percuataneous ethanol injection; RFA, radiofrequency ablation; SBRT, stereotactic body radiotherapy; HCC, hepatocellular carcinoma; PVT, portal vein thrombosis; EHM, extrahepatic metastasis; IVCT, inferior vena cava thrombosis; VMAT, volumetric modulated arc therapy; 3D-CRT, 3D conformal radiotherapy; IMRT, intensity modulated radiotherapy; KPS, Karnofsky performance status; LN, lymph node; SD, stable disease; PR, partial response; PD, progressive disease; ECOG, Eastern Cooperative Oncology Group.

###### 

Clinical outcomes of TACE+RT for hepatocellular carcinoma

  Reference                                          Design                                                  Patient number                                                         RT dose                                                                       Response rate                                                                            Survival
  -------------------------------------------------- ------------------------------------------------------- ---------------- ----------------------------------------------------- ----------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- --------------------------------------------------
  Prospective studies                                                                                                                                                                                                                                                                                                                                      
  Li B, et al. \[[@b40-cmh-2017-0073]\] (2003)       Phase II, TACE+RT                                       45               All stage III, KPS ≥70, CP A, B                       45 Gy25 fx -\> boost 5.4 Gy/3 fx                                              CR6, PR 35, SD 4, PD 0                                                                   1-yr 69%, 2-yr 48%, 3-yr 23%, median 23.5 months
  Oh D, et al. \[[@b41-cmh-2017-0073]\] (2010)       Phase II, TACE+RT                                       40               HCC which failed after 1-2 courses of TACE            Median 54 Gy in 3 Gy/fx                                                       Objective response rate: 63% (CR 9, PR 18), 9 progressions within the irradiated field   1-yr 72%, 2-yr 46%
  Leng ZQ, et al. \[[@b42-cmh-2017-0073]\] (2000)    Phase III, TACE+RT vs. TACE                             36 vs. 39        Stage II, III, IVA, KPS ≥65, CP A                     27.6--33.6 Gy to 'volume including whole live area-\>11.4--32.4 Gy boost                                                                                               1-yr 75% vs. 61%, 2-yr 57% vs. 34%
  Zhao MH, et al. \[[@b43-cmh-2017-0073]\] (2006)    Phase III, TACE+RT vs. TACE                             49 vs. 47        T1-2N0M0, KPS ≥70, CP A, PVT (-)                      45-55 Gy                                                                      TACE+RT: CR 17, PR 18, PD 5, TACE: CR 8, PR 11, PD 11                                    1-yr 82% vs. 55%, 2-yr 63% vs. 28%
  Koo JE, et al. \[[@b44-cmh-2017-0073]\] (2010)     Phase II, TACE+RT (vs. historical control TACE alone)   42 vs. 29        All with IVCT, CP A, B                                Median 45 Gy in 2.5-5 Gy/fx (determined by the extent of thrombosis)          Objective response rate: 43% vs. 14%                                                     Median 12 vs. 5 months, 1-yr 48% vs. 17%
  Choi C, et al. \[[@b45-cmh-2017-0073]\] (2014)     Phase II, TACE+RT                                       31               HCC which failed after 1-3 courses of TACE, CP A, B   Median 54 Gy in 1.8-2 Gy/fx                                                   In-field CR 24%, PR 59% at 12 wks Overall CR 10%, PR 52% at 12 wks                       2-yr 61%
  Retrospective studies                                                                                                                                                                                                                                                                                                                                    
  Cheng JC, et al. \[[@b46-cmh-2017-0073]\] (2000)   TACE+RT or RT alone                                     16, 6            Stage II-IV, CP A, B, median 10 cm                    46.9 ± 5.9 Gy in 1.8-2 Gy/fx                                                  Only 3 local prgression (area treated with RT)                                           1-yr 54%, 2-yr 41%, median 19.2 months
  Guo WJ, et al. \[[@b47-cmh-2017-0073]\] (2003)     TACE+RT vs. TACE                                        76 vs. 89        Stage I-III, KPS ≥70, CP A, B                         1.8--2.0 Gy/fx\* 15--28fx                                                     Objective response rate: 47% vs. 28%                                                     1-yr 64% vs. 40%
  Li Y, et al. \[[@b48-cmh-2017-0073]\] (2003)       TACE+RT vs. TACE                                        41 vs. 41        Size: 3.2-11.5 cm, CP A, B                            PTV \<216 cm^3^: 5--8 Gy/fx\* 5--12fx, PTV \> 216 cm^3^: 4 Gy/fx\* 11-14 fx   TACE+RT: CR 4, PR 23 TACE: CR 1, PR 23                                                   1-yr 73% vs. 55%
  Zeng ZC, et al. \[[@b36-cmh-2017-0073]\] (2004)    TACE+RT vs. TACE                                        54 vs. 203       Size\>10 cm: overall 31%, CP A, B                     2 Gy/fx\* 18-30 fx                                                            CR+PR: 76% vs. 31%                                                                       1-yr 72% vs. 60%, 3-yr 24% vs. 11%
  Chen WJ, et al. \[[@b49-cmh-2017-0073]\] (2014)    TACE+RT vs. TACE                                        78 vs. 80                                                                                                                                            Objective response rate: 72% vs. 54%                                                     1-yr 78% vs. 59%, 3-yr 26% vs .16%
  Shim SJ, et al. \[[@b37-cmh-2017-0073]\] (2005)    TACE+RT vs. TACE                                        38 vs. 35        Stage III, IV, stage ≥5 cm, CP A, B                   1.8 Gy/fx\* 17--33fx                                                          TACE+RT: CR 0, PR 25                                                                     2-yr 37% vs. 14% (benefit twith large tumors)

KPS, Karnofsky performance status; CP, child-pugh; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; HCC, hepatocellular carcinoma; PVT, portal vein thrombosis; IVCT, inferior vena cava thrombosis; TACE, transcatheter arterial chemoembolization; RT, radiotherapy; PTV, planning target volume.

###### 

Clinical outcomes of RT-combining treatments for hepatocellular carcinoma with portal vein thrombosis

  Reference                                            Institutions                                                  Patient number   MVI site                                          RT dose                                                                                              Combined Tx                                             Response rate                                                           Survival
  ---------------------------------------------------- ------------------------------------------------------------- ---------------- ------------------------------------------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  Prospective studies                                                                                                                                                                                                                                                                                                                                                                                                        
  Yamada K, et al. \[[@b53-cmh-2017-0073]\] (2003)     Japan, Kobe Univ.                                             19               All: 1st PVTT                                     60 Gy/30 fx                                                                                          TACE in all pts                                         CR+PR 58%                                                               Median: 7 months, 1-yr: 40.6%
  Han KH, et al. \[[@b54-cmh-2017-0073]\] (2008)       Korea, Yonsei Cancer Center                                   40               Main: 13                                          45 Gy/25 fx                                                                                          CCRT with IACTx followed by IACTx                       CR 0 PR 45% SD 23%                                                      Median 13.1 months, 1-yr 57.6%
  1st: 27                                                                                                                                                                                                                                                                                                                                                                                                                    
  Shirai S, et al. \[[@b55-cmh-2017-0073]\] (2010)     Japan, Wakayama Medical Univ.                                 19               Main: 12                                          45 Gy/18 fx                                                                                          TACE in all pts                                         For PVTT: CR 0% PR 37% SD 53%                                           Median 10.3 months, 1-yr 47%
  1st: 7                                                                                                                                                                                                                                                                                                                                                                                                                     
  Koo JE, et al. \[[@b44-cmh-2017-0073]\] (2010)       Korea, AMC                                                    42               IVCTT 42 (co-existence of PVTT in 19 pts)         28-50 Gy (median 45 Gy)                                                                              TACE in all pts                                         CR 14% PR 29% SD 29%                                                    Median 11.7 months, 1-yr 47.7%
  Chuma M, et al. \[[@b56-cmh-2017-0073]\] (2011)      Japan, Hokkaido Univ.                                         20               All: main, 1st PVTT                               30-48 Gy/7-16 fx                                                                                     CCRT                                                    CR 0% PR 35% SD 45%                                                     Median 12 months, 1-yr n-s
  Park MS, et al. \[[@b57-cmh-2017-0073]\] (2013)      Korea, Yonsei Cancer Center                                   30               All: 1st PVTT                                     45 Gy/25 fx                                                                                          TACE followed by CCRT with IACTx                        CR 0% PR 30% SD 40%                                                     Median 9.8 months, 1-yr n-s
  Retrospective studies                                                                                                                                                                                                                                                                                                                                                                                                      
  Katamura Y, et al. \[[@b58-cmh-2017-0073]\] (2009)   Japan, Hiroshima Univ.                                        16               All: main, 1st PVTT                               30,39,45 Gy/10,13,15 fx                                                                              CCRT with IACTx (5FU+IFN) in all pts                    For PVTT: CR 19% PR 56% SD 25%                                          Median 7.5 months, 1-yr n-s
  Yu JI, et al. \[[@b38-cmh-2017-0073]\] (2011)        Korea, SMC                                                    281              SMV 13, Main PVTT 114, Both 1st 4, 1st PVTT 150   30-54 Gy, BED 39-70.2 Gy10                                                                           TACE in 90%, Others: reRT, RFA, sorafenib, op           CR 4% PR 50% SD 26%                                                     Median 11.6 months, 1-yr 48.1%
  Yoon SM, et al. \[[@b59-cmh-2017-0073]\] (2012)      Korea, AMC                                                    412              Main or 1st PVTT 300, other PVTT 212              21-60 Gy (median 40 Gy), BED 27.3-78 Gy10 (median 51.75 Gy10)                                        TACE in almost all pts                                  HCC: CR 4%, PR 24%, SD 8% PVTT: CR 7%, PR 33%, SD 46%                   Median 10.6 months, 1-yr 42.5%
  Hou JZ, et al. \[[@b60-cmh-2017-0073]\] (2012)       China, Fudan Univ.                                            181              Main PVTT 87                                      30-60 Gy (median 50 Gy)                                                                              TACE, as possible as                                    PVTT: CR 21%, PR 33%, SD 39% IVCTT: CR 55%, PR 27%, SD 18%              Median: main PVTT 7.4 months, branch 10.2 months, IVC 17.4 months, both 8.5 months 1-yr: main PVTT 36%, branch 49%, IVC 68%, both 42%
  Branch PV 39                                                                                                                                                                                                                                                                                                                                                                                                               
  IVC 37                                                                                                                                                                                                                                                                                                                                                                                                                     
  IVC+PV 18                                                                                                                                                                                                                                                                                                                                                                                                                  
  Tang QH, et al. \[[@b61-cmh-2017-0073]\] (2013)      China, 2 institutions                                         185              Main 49                                           30-52 Gy (median 40 Gy), BED 39-75 Gy10                                                              TACE in all pts                                         N-S                                                                     Median 12.3 months, 1-yr 51.6%
  1st 64                                                                                                                                                                                                                                                                                                                                                                                                                     
  2nd 72                                                                                                                                                                                                                                                                                                                                                                                                                     
  Cho JY, et al. \[[@b62-cmh-2017-0073]\] (2014)       Korea, SMC                                                    67               MVI 64 (Main PVTT 17)                             30-45 Gy/10-22 fx BED 39-65.25 Gy10 (median 47.25 Gy10)                                              TACE in all pts                                         N-S                                                                     Median 14.1 months, 1-yr n-s
  Tanaka Y, et al. \[[@b63-cmh-2017-0073]\] (2014)     Japan, Kitasato Univ.                                         67               1st PVTT 25                                       30-56 Gy                                                                                             N-S                                                     CR 7% PR 37% SD 24% PVTT RR 45%; HV RR 59% Both20%                      Median 9.4 months, 1-yr 39%
  Main PVTT 15                                                                                                                                                                                                                                                                                                                                                                                                               
  1st HV 4                                                                                                                                                                                                                                                                                                                                                                                                                   
  IVC 13                                                                                                                                                                                                                                                                                                                                                                                                                     
  PVTT+HVI 10                                                                                                                                                                                                                                                                                                                                                                                                                
  Yu JI, et al. \[[@b64-cmh-2017-0073]\] (2014)        Korea, Multicenter                                            994              PVTT 994                                          7.2-66 Gy (median 45 Gy), BED 8.5-137.7 Gy10 (median 56.25 Gy10)                                     TACE in almost all pts                                  PVTT CR 5% PR 41% SD 41%                                                Median 9.2 months, 1-yr 40%
   -main 497                                                                                                                                                                                                                                                                                                                                                                                                                 
   - others497                                                                                                                                                                                                                                                                                                                                                                                                               
  Duan F, et al. \[[@b65-cmh-2017-0073]\] (2015)       China, General Hospital of Chinese People's Liberation Army   11               IVC and RA 11                                     60 Gy/30 fx                                                                                          TACE in all pts                                         IVC & RA: CR 100% HCC: CR 18%, PR 55% SD 18%                            Median 21 months, 1-yr 54.5%
  Yu JI, et al. \[[@b66-cmh-2017-0073]\] (2016)        Korea, SMC & AMC                                              508              PVTT 508                                          BED 27.3-78 Gy10 (median 54.6 Gy10) for training, 15.6-71.5 Gy10 (median 50.4 Gy10) for validation   TACE in almost all pts                                  PVTT Training: CR 10%, PR 41%, SD 39%                                   N-S
   -main 217                                           Validation: CR 10%, PR 54%, SD 24%                                                                                                                                                                                                                                                                                                                                    
   -others 291                                                                                                                                                                                                                                                                                                                                                                                                               
  Im JH, et al. \[[@b67-cmh-2017-0073]\] (2017)        Korea, Multicenter                                            985              All: main, 1st PVTT                               12-66 Gy (median 45 Gy) in 1.8-17 Gy                                                                 TACE/TACI 80%, HAIC 16%, TACE/TACI+HAIC 4%, no Tx 33%   PVTT: CR 6%, PR 46%, SD 40%, PD 8%, HCC: CR 5%, PR 48%, SD 39%, PD 8%   Median 20 months, 1-yr 43%, 2-yr 22%

PVTT, portal vein tumor thrombosis; IVCTT, inferior vena cava tumor thrombosis; HV, hepatic vein; RA, right atrium; TACE, transcatheter arterial chemoembolization; TACI, transcatheter arterial chemoinfusion; CR, complete response; PR, partial response; SD, stable disease; CCRT, concurrent chemoradiotherapy; IACTx, intraarterial chemotherapy; BED, biologically equivalent dose; RR, response rate.

###### 

Clinical outcomes of proton therapy for hepatocellular carcinoma

  Reference                                             Institutions                           Design          Patient number   Indication                                  Median size (cm)                                                      Dose                                                                 Median f/u (range), mo   Local control                                                                             Overall survival                                       Adverse events
  ----------------------------------------------------- -------------------------------------- --------------- ---------------- ------------------------------------------- --------------------------------------------------------------------- -------------------------------------------------------------------- ------------------------ ----------------------------------------------------------------------------------------- ------------------------------------------------------ ---------------------------------------------------------------------------------
  Chiba T, et al. \[[@b88-cmh-2017-0073]\] (2005)       Japan, Tsukuba                         Retrospective   162                                                          \<3:27%, 3-5:56%, 5\<:17%                                             72 GyE/16 fx, 78GyE/ 20 fx, 84 GyE/24 fx, 50 GyE/10 fx                                        87% (5-yr)                                                                                24% (5-yr)                                             Very few acute reactions, 5 ≥Gr 2 toxicity
  Fukuda K, et al. \[[@b95-cmh-2017-0073]\] (2017)      Japan, Tsukuba                         Retrospective   129              CP A or B, ECOG 0-2, previously untreated   3.9                                                                   77 GyE/35 fxl 72.6 GyE/22 fx, 66 GyE/10 fx (according to location)   55 (43-67)               94% (5-yr)                                                                                69% (0/A stage), 66% (B stage), 25% (C stage) (5-yr)   No ≥Gr 2 late toxicity, radiation dermatitis was common, but no ≥Gr 3 toxicity
  Bush DA, et al. \[[@b89-cmh-2017-0073]\] (2011)       United States, Loma Linda University   Phase I         76               CP A, B, or C, All with cirrhosis           5.5                                                                   63 GyE/15 fx                                                                                  Local control: 60/76                                                                      Median PFS 36 months                                   5 Gr2 toxicities, no significant overall deterioration of liver function
  Hong TS, et al. \[[@b91-cmh-2017-0073]\] (2014)       United States, MGH                     Phase I         15               CP A or B                                   CTV: median 124 (20-581) cc                                           45-75 GyE/15 fx                                                      69 (for survivors)       No infield recurrence, Marginal recurrence: 1/15                                          33% (3-yr), Median 12 months                           2 Gr 3 bilirubinemia, 1 Gr 3 gastrointestinal bleed, 1 Gr 5 stomach perforation
  Kim TH, et al. \[[@b93-cmh-2017-0073]\] (2015)        Korea, NCC                             Phase I         27               ≤6cm, CP A or B                             3.2 for dose level I, 2.3 for dose level II, 2.5 for dose level III   60 GyE/20 fx, 66 GyE/22 fx, 72 GyE/24 fx                                                      71-83% (3-yr), CR: 63% for dose level I, 57% for dose level II, 100% for dose level III   42% (5-yr), Median 38 months                           No ≥Gr 2 late toxicity
  Kawashima M, et al. \[[@b94-cmh-2017-0073]\] (2005)   Japan, NCC Hospital East               Phase II        30               All with cirrhosis, R15 ≥ 15%, CP A or B    4.5                                                                   76 GyE/20 fx                                                         31                       96% (2-yr)                                                                                66% (2-yr)                                             8 hepatic insufficiencies, no hepatic insufficiency when ICG R15 \<20%
  Fukumitsu N, et al. \[[@b95-cmh-2017-0073]\] (2009)   Japan, Tsukuba                         Phase II        51               CP A or B                                   2.8                                                                   66 GyE/10 fx                                                         34                       88% (5-yr)                                                                                39% (5-yr)                                             8 CPS deteriorations, late: 3 rib fractures, 1 Gr 3 radiation pneumonitis
  Hong TS, et al. \[[@b92-cmh-2017-0073]\] (2016)       United States, MGH                     Phase II        49               CP A or B                                   5                                                                     58.05-67.5 GyE/15 fx                                                 19.5 (for survivors)     95% (2-yr)                                                                                63% (2-yr), Median 49.9 months                         4 Gr 3 toxicities
  PVTT (+)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Lee SU, et al. \[[@b97-cmh-2017-0073]\] (2014)        Korea, NCC                             Retrospective   27               PVTT(+), CP A or B                          7                                                                     50-66 GyE/20-22 fx                                                   13 (2-52)                Objective response rate: 63% for primary tumor, 56% for PVTT, local recurrence: 9/27      33% (2-yr), Median 13 months                           No ≥Gr 3 toxicity
  Sugahara S, et al. \[[@b98-cmh-2017-0073]\] (2009)    Japan, Tsukuba                         Retrospective   35               PVTT(+), CP A or B                          6                                                                     72.6 GyE/22 fx                                                       21 (2-88)                CR: 8/35, PR: 21/35, local PFS: 20% (5-yr)                                                Median 22 months, 48% (5-yr)                           3 ≥Gr 3 acute toxicity, No ≥Gr 3 late toxicity
  Hata M, et al. \[[@b99-cmh-2017-0073]\] (2005)        Japan, Tsukuba                         Retrospective   12               PVTT(+), CP A or B                          6                                                                     50-72 GyE/10-22 fx                                                   28 (4-88)                CR: 2/12, PR: 10/12                                                                       58% (5-yr)                                             Mild acute toxicities, low late toxicity rate (3 mild telangiectasia)

CP, child-pugh; ECOG, Eastern Cooperative Oncology Group; CR, complete response; PR, partial response; PFS, progression free survival; PVTT, portal vein tumor thrombosis; CTV, clinical target volume; ICG, Indocyanine green.
